- NCBI Gene Id:
- Protein Name:
- Tumor necrosis factor receptor superfamily member 5
- Alias Symbols:
- p50, Bp50, CDW40, MGC9013, TNFRSF5, CD40
- Replacement Item:
- This antibody may replace item sc-112948 from Santa Cruz Biotechnology.
- Description of Target:
- MOUSE ANTI HUMAN CD40
- Protein Size (# AA):
- IHC-AFF, FC, IP, IHC-FFPE
- Tissue Tool:
- Find tissues and cell lines supported by DNA array analysis to express CD40.
- RNA Seq:
- Find tissues and cell lines supported by RNA-seq analysis to express CD40.
- Predicted Species Reactivity:
- Predicted Homology Based on Immunogen Sequence:
- Product Format:
- Purified IgG - liquid
- Reconstitution and Storage:
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Printable datasheet for anti-CD40 antibody - OASA01969
- Application Info:
- Flow Cytometry: 20ug/ml
Immunohistology - Frozen: 1ug/ml - 10ug/ml
Immunohistology - Paraffin(1): 1ug/ml - 10ug/ml
(1) Special conditions apply - Please see [*]
- Application Data:
- Application #1: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40: Alexa Fluor 488
Application #2: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:Alexa Fluor 647
Application #3: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:Biotin
Application #4: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:FITC
Application #5: Staining of human peripheral blood lymphocytes with Mouse anti Human CD40:RPE
- Additional Information:
- Fusion Partners: Spleen cells from immunised BALB/c mice were fused with cells of the mouse NS1 myeloma cell line.
Histology Positive Control Tissue: Human Tonsil
- Preparation: Purified IgG prepared by affinity chromatography on Protein A
Preservative Stabilisers: 0.09% - Sodium Azide
- Approx Protein Conc: IgG concentration 1.0 mg/ml
Buffer Solutions: Tris buffered saline
- Protocol Information:
- Citation: 1: Förster R, Emrich T, Kremmer E, Lipp M. Expression of the G-protein—coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood. 1994 Aug 1;84(3):830-40. PubMed PMID: 7913842.
Experiment Name: Cell culture
Experiment Background: 1. Interestingly, activation of both mature B and T cells by CD40 MoAb and CD3 MoAb, respectively, led to complete downregulation of BLRI.2. Downregulation of BLRl on activated B and T cells. CD19+ tonsillar lymphocytes were isolated by MACS. Cells were cultured on irradiated mouse fibroblasts transfected with the human Fc-receptor in the presence of anti-CD40 MoAb and IL-4.
Experimental Steps: 1. B cells were cultured in Iscove’s medium supplemented with 5 µg/mL bovine insulin, 0.5% bovine serum albumin (BSA), 50 µg/mL human transferin, 5 X 10-5 mol/L β-mercaptoethanol (β-ME) (all from Sigma), and 5% IgG-free FCS (PAA, Linz, Austria). 2. All cultures were performed in the presence of irradiated (8,000 rad) CDw32-transfected Ltk- cells (CDw32 L cells), kindly provided by K. Moore (DNAX, Palo Alto, CA). CDw32 L cells were seeded in 48-well flat-bottom microtiter plates at 2 X 104/well 1 day before MACS-separated CD19+ B cells were added at 5 X 105/well. 3. At the beginning of the experiment, 100 U/mL recombinant human interleukin-4 (rhuIL-4; Genzyme, Cambridge, MA) and 1 pg/mL anti-CD40 MoAb (clone B-B20) were added to give a final volume of 500 uL. 4. Half of the supplemented medium was replaced every other day. BLRl expression of triplicate cultures of B cells was monitored over a 10-day period by flow cytometry. 5. T cells were cultured in RPM1 1640 medium supplemented with 10% FCS and 5 X 10-5 mol/L β-mercaptoethanol (β-ME). 6. For T-cell activation, 24-well plates were coated overnight with anti-CD3 MoAb (clone 26-11-8; 50 ug/mL in carbonate buffer, pH 9.6). 7. After washing extensively with PBS, PBLs were added at 2.5 X 105/well and BLRl expression of CD3+ cells was monitored as described for B cells.
Number Of Protocols: 1
- Target Reference:
- 1. Quadbeck, B. et al. (2002) Maturation of thyroidal dendritic cells in Graves Disease. Scand. J. Immunol. 55: 612-620.
2. Kirsch, B. M. et al . (2005) The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res. Ther. 7: R694-R703.
3. Cheadle, E. et al. (2003) Mycobacterium bovis bacillus Calmette-Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism. Immunology.108: 79-88.
4. Carpenter, E.L. et al. (2009) Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 7: 93.
5. Garcia-Nieto, S. et al. (2010) Laminin and Fibronectin Treatment Leads to Generation of Dendritic Cells with Superior Endocytic Capacity. PLoS ONE. 5: 1-10.
6. Wang, Y.S. et al. (2007) Characterization of canine monocyte-derived dendritic cells with phenotypic and